REMICADE Antitrust Settlement Receives Final Approval
LexBlog IP
APRIL 12, 2023
alleging that they engaged in anticompetitive conduct relating to the sale and marketing of J&J’s REMICADE (infliximab). The court preliminarily approved the settlement in August 2022. The post REMICADE Antitrust Settlement Receives Final Approval appeared first on Big Molecule Watch. million in expenses.
Let's personalize your content